Loading…
Niki BioSolutions, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in NIKI.
▼ -98.0% over 5Y.
today you would have $18.59▼ -98.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 8 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $10.60 | $28.00 | $24.49 | $55.00 | $150.00 | $247.00 | $1,585.00 | $1,518.00 | |
| P/E | — | — | — | — | — | — | 12.3x | — | — |
| P/S | 25.7x | — | — | 25.7x | 15.1x | 34.1x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| KAPAKairos Pharma, LTD. | $0.24 | — | 1.2x | — | -113.96% | $5.62M |
| WOKWORK Medical Technology Group LTD | $2.33 | — | 0.0x | — | -19.23% | $5.63M |
| YCBDcbdMD, Inc. | $0.50 | 2.2x | 0.6x | — | -40.33% | $5.6M |
| LIMNLiminatus Pharma, Inc. | $4.23 |
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| P/B | 1.6x | 0.3x | 0.7x | 0.4x | 1.2x | 2.2x | 1.9x | 28.1x | 12.8x |
| EPS | -$1.90 | -$7.80 | -$6.20 | -$27.50 | -$71.50 | $20.00 | -$64.00 | -$53.00 |
| Profit margin | -756.20% | — | — | -654.80% | -756.20% | -1624.64% | — | — | — |
| ROE | -32.49% | -5.90% | -20.19% | -11.37% | -62.37% | -106.10% | 11.76% | -122.96% | -44.79% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| — |
| $5.68M |
| ZCMDZhongchao Inc. | $0.92 | — | 0.1x | — | -24.88% | $5.69M |
| NCNANuCana plc | $1.33 | 0.0x | 0.2x | — | -70.26% | $5.54M |